Case Studies
Real-world evidence of how IDDCR delivers measurable outcomes across clinical trials, data management, biometrics and regulatory submissions.
Phase IIIA global Phase III oncology sponsor faced a backlog of 4,200 outstanding queries at the 90-day pre-lock window, threatening a 6-week submission delay.
Phase II / IIIA rare disease biotech needed SDTM-compliant datasets across 12 studies with heterogeneous EDC configurations, facing an FDA submission deadline in 14 months.
Phase IIA mid-size neurology sponsor required full-service CRO support for a 22-country, 340-patient Phase II study with complex eligibility criteria and a 12-month enrolment target.
Post-MarketingA pharmaceutical company with a growing cardiovascular portfolio needed to establish a scalable, EMA-compliant signal detection and aggregate reporting function within 90 days.
Phase II / IIIA sponsor required biostatistics support for a seamless Phase II/III adaptive design with an interim analysis, requiring rapid turnaround of the SAP and blinded sample size re-estimation.
Tell us about your study and we'll show you how IDDCR can deliver measurable results for your programme.
